RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

Part of paid clinical trials in Philadelphia, Pennsylvania.

Sponsor
Abramson Cancer Center at Penn Medicine
Study ID
NCT04827862
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Non Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Pembrolizumab — DRUG
    pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy

Study Details

This study is an open-label Phase II trial of non-Hodgkin lymphoma patients receiving initial treatment with the immunomodulatory agent, pembrolizumab, plus low-dose (4 Gy x 5) involved-site radiotherapy. Eligible patients will have r/r disease with at least 2 sites of measurable disease (≥1.0 cm), and must be eligible for treatment with pembrolizumab. Biosamples (blood and, where available, tumor) will be collected as outlined below. Pembrolizumab will be continued after RT until disease progression, drug intolerance, or at the discretion of the treating medical oncologist.

Key Dates

Start date
Jul 1, 2022
Status verified
Dec 2025
Primary completion
Jun 1, 2026
Completion
Nov 30, 2026

Study Design

Enrollment
6 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Pembrolizumab and Radiation Therapy
    pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy

Primary Outcome Measure

CR rate [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Abamson Cancer Center of the University of PennsylvaniaPhiladelphiaPennsylvania19104-

Find similar trials in Philadelphia, PA

By research site
Abamson Cancer Center of the University of Pennsylvania· Philadelphia, PA

Related Studies